Literature DB >> 17030564

Modification of enrofloxacin treatment regimens for poultry experimentally infected with Salmonella enterica serovar Typhimurium DT104 to minimize selection of resistance.

Luke P Randall1, Sue W Cooles, Nick C Coldham, Ken S Stapleton, Laura J V Piddock, Martin J Woodward.   

Abstract

We hypothesized that higher doses of fluoroquinolones for a shorter duration could maintain efficacy (as measured by reduction in bacterial count) while reducing selection in chickens of bacteria with reduced susceptibility. Chicks were infected with Salmonella enterica serovar Typhimurium DT104 and treated 1 week later with enrofloxacin at the recommended dose for 5 days (water dose adjusted to give 10 mg/kg of body weight of birds or equivalence, i.e., water at 50 ppm) or at 2.5 or 5 times the recommended dose for 2 days or 1 day, respectively. The dose was delivered continuously (ppm) or pulsed in the water (mg/kg) or by gavage (mg/kg). In vitro in sera, increasing concentrations of 0.5 to 8 microg/ml enrofloxacin correlated with increased activity. In vivo, the efficacy of the 1-day treatment was significantly less than that of the 2- and 5-day treatments. The 2-day treatments showed efficacy similar to that of the 5-day treatment in all but one repeat treatment group and significantly (P < 0.01) reduced the Salmonella counts. Dosing at 2.5x the recommended dose and pulsed dosing both increased the peak antibiotic concentrations in cecal contents, liver, lung, and sera as determined by high-pressure liquid chromatography. There was limited evidence that shorter treatment regimens (in particular the 1-day regimen) selected for fewer strains with reduced susceptibility. In conclusion, the 2-day treatment would overall require a shorter withholding time than the 5-day treatment and, in view of the increased peak antibiotic concentrations, may give rise to improved efficacy, in particular for treating respiratory and systemic infections. However, it would be necessary to validate the 2-day regimen in a field situation and in particular against respiratory and systemic infections to validate or refute this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030564      PMCID: PMC1694010          DOI: 10.1128/AAC.00525-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Administration of enrofloxacin and capsaicin to chickens to achieve higher maximal serum concentrations.

Authors:  O L Gutierrez; L H Sumano; Q M Zamora
Journal:  Vet Rec       Date:  2002-03-16       Impact factor: 2.695

2.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

3.  Monitoring Mycoplasma gallisepticum and Mycoplasma synoviae infection in breeder chickens after treatment with enrofloxacin.

Authors:  W A Stanley; C L Hofacre; G Speksnijder; S H Kleven; S E Aggrey
Journal:  Avian Dis       Date:  2001 Apr-Jun       Impact factor: 1.577

4.  Treatment of chronic salmonella carriers with ciprofloxacin.

Authors:  G Diridl; H Pichler; D Wolf
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

5.  Detection of mutations in Salmonella enterica gyrA, gyrB, parC and parE genes by denaturing high performance liquid chromatography (DHPLC) using standard HPLC instrumentation.

Authors:  L P Randall; N G Coldham; M J Woodward
Journal:  J Antimicrob Chemother       Date:  2005-09-01       Impact factor: 5.790

6.  Efficacy of tilmicosin in the control of experimental Mycoplasma gallisepticum infection in chickens.

Authors:  I Kempf; L Reeve-Johnson; F Gesbert; M Guittet
Journal:  Avian Dis       Date:  1997 Oct-Dec       Impact factor: 1.577

7.  Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens.

Authors:  B Charleston; J J Gate; I A Aitken; B Stephan; R Froyman
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  The O-antigen of Salmonella enterica serotype Enteritidis PT4: a significant factor in gastrointestinal colonisation of young but not newly hatched chicks.

Authors:  P Carroll; R M La Ragione; A R Sayers; M J Woodward
Journal:  Vet Microbiol       Date:  2004-08-19       Impact factor: 3.293

9.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  6 in total

1.  Phenotypic-genotypic resistance in Salmonella spp. isolated from cattle carcasses from the north central zone of the State of Mexico.

Authors:  Jorge Antonio Varela-Guerrero; Martin Talavera-Rojas; Adriana del Carmen Gutiérrez-Castillo; Nydia Edith Reyes-Rodríguez; Jesús Vázquez-Guadarrama
Journal:  Trop Anim Health Prod       Date:  2012-12-07       Impact factor: 1.559

Review 2.  The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way forward.

Authors:  Frank M Aarestrup
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-05       Impact factor: 6.237

3.  The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium.

Authors:  Jun Li; Haihong Hao; Guyue Cheng; Xu Wang; Saeed Ahmed; Muhammad Abu Bakr Shabbir; Zhenli Liu; Menghong Dai; Zonghui Yuan
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

4.  Risks Involved in the Use of Enrofloxacin for Salmonella Enteritidis or Salmonella Heidelberg in Commercial Poultry.

Authors:  Eduardo Morales-Barrera; Nicole Calhoun; Jose L Lobato-Tapia; Vivian Lucca; Omar Prado-Rebolledo; Xochitl Hernandez-Velasco; Ruben Merino-Guzman; Victor M Petrone-García; Juan D Latorre; Brittany D Mahaffey; Kyle D Teague; Lucas E Graham; Amanda D Wolfenden; Mikayla F A Baxter; Billy M Hargis; Guillermo Tellez
Journal:  Front Vet Sci       Date:  2016-08-31

5.  Editorial: Alternatives to Antimicrobial Growth Promoters and Their Impact in Gut Microbiota, Health and Disease.

Authors:  Guillermo Tellez; Juan D Latorre
Journal:  Front Vet Sci       Date:  2017-11-10

6.  Longitudinal study on the effects of growth-promoting and therapeutic antibiotics on the dynamics of chicken cloacal and litter microbiomes and resistomes.

Authors:  Chhedi Lal Gupta; Shlomo E Blum; Karuppasamy Kattusamy; Tali Daniel; Shelly Druyan; Roni Shapira; Oleg Krifucks; Yong-Guan Zhu; Xin-Yuan Zhou; Jian-Qiang Su; Eddie Cytryn
Journal:  Microbiome       Date:  2021-08-28       Impact factor: 14.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.